Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C

Virology

Volumn 375, Issue 2, 2008, Pages 580-591

  Li, Hui ^a   McMahon, Brian J ^b,c   McArdle, Susan ^a   Bruden, Dana ^b   Sullivan, Daniel G ^a   Shelton, Dave ^a   Deubner, Heike ^a   Gretch, David R ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c ALASKA NATIVE MEDICAL CENTER   (United States)

Author keywords

Chronic liver disease; Envelope glycoprotein; Hepatitis C virus; Viral evolution; Viral fitness

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2;

AGED; ALCOHOL CONSUMPTION; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; COEVOLUTION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE ISOLATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; MOLECULAR DYNAMICS; PHYLOGENY; PRIORITY JOURNAL; VIRUS LOAD;

AMINO ACID SEQUENCE; EVOLUTION, MOLECULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 43249089764     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.02.012     Document Type: Article

References (98)

1. Alfonso V., Flichman D.M., Sookoian S., Mbayed V.A., and Campos R.H. Evolutionary study of HVR1 of E2 in chronic hepatitis C virus infection. J. Gen. Virol. 85 (2004) 39-46
2. Allain J.P., Dong Y., Vandamme A.M., Moulton V., and Salemi M. Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J. Virol. 74 (2000) 2541-2549
3. Allison S.L., Schalich J., Stiasny K., Mandl C.W., and Heinz F.X. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J. Virol. 75 (2001) 4268-4275
4. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., and Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341 (1999) 556-562
5. Arenas J.I., Gallegos-Orozco J.F., Laskus T., Wilkinson J., Khatib A., Fasola C., Adair D., Radkowski M., Kibler K.V., Nowicki M., Douglas D., Williams J., Netto G., Mulligan D., Klintmalm G., Rakela J., and Vargas H.E. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J. Infect. Dis. 189 (2004) 2037-2046
6. Bartosch B., Dubuisson J., and Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197 (2003) 633-642
7. Booth J.C., Kumar U., Webster D., Monjardino J., and Thomas H.C. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27 (1998) 223-227
8. Bruden D.L., McMahon B.J., Hennessy T.W., Christensen C.J., Homan C.E., Williams J.L., Sullivan D.G., Gretch D.R., Cagle H.H., and Bulkow L.R. Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera. Am. J. Gastroenterol. 99 (2004) 1517-1522
9. Bukh J., Miller R.H., and Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15 (1995) 41-63
10. Choisy M., Woelk C.H., Guegan J.F., and Robertson D.L. Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J. Virol. 78 (2004) 1962-1970
11. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
12. Curran R., Jameson C.L., Craggs J.K., Grabowska A.M., Thomson B.J., Robins A., Irving W.L., and Ball J.K. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J. Gen. Virol. 83 (2002) 11-23
13. Deleersnyder V., Pillez A., Wychowski C., Blight K., Xu J., Hahn Y.S., Rice C.M., and Dubuisson J. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 71 (1997) 697-704
14. Di Bisceglie A.M. Hepatitis C. Lancet 351 (1998) 351-355
15. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., McKinney D., Sette A., Hughes A.L., and Walker C.M. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15 (2001) 883-895
16. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., Shapiro M., and Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7792-7796
17. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H.J., and Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 15394-15399
18. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., and Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 (2000) 339-344
19. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., Peddis G., Usai F., Serra G., Chessa L., Diaz G., Balestrieri A., and Purcell R.H. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3081-3086
20. Fattovich G., Giustina G., Degos F., Tremolada F., Diodati G., Almasio P., Nevens F., Solinas A., Mura D., Brouwer J.T., Thomas H., Njapoum C., Casarin C., Bonetti P., Fuschi P., Basho J., Tocco A., Bhalla A., Galassini R., Noventa F., Schalm S.W., and Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997) 463-472
21. Felsenstein J. PHYLIP - Phylogeny Inference Package Version 3.5 (1993), Department of Genetics, University of Washington, Seattle, WA
22. Fournillier A., Wychowski C., Boucreux D., Baumert T.F., Meunier J.C., Jacobs D., Muguet S., Depla E., and Inchauspe G. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J. Virol. 75 (2001) 12088-12097
23. Garry R.F., and Dash S. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology 307 (2003) 255-265
24. Gaud U., Langer B., Petropoulou T., Thomas H.C., and Karayiannis P. Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J. Med. Virol. 69 (2003) 350-356
25. Goffard A., and Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie 85 (2003) 295-301
26. Goffard A., Callens N., Bartosch B., Wychowski C., Cosset F.L., Montpellier C., and Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79 (2005) 8400-8409
27. Gretch D.R., Bacchi C.E., Corey L., Dela Rosa C., Lesniewski R.R., Kowdley K., Gown A., Frank I., Perkins J.D., and Carithers Jr. R.L. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 22 (1995) 1-9
28. Gretch D.R., Polyak S.J., Wilson J.J., Carithers Jr. R.L., Perkins J.D., and Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J. Virol. 70 (1996) 7622-7631
29. Hiramatsu N., Hayashi N., Haruna Y., Kasahara A., Fusamoto H., Mori C., Fuke I., Okayama H., and Kamada T. Immunohistochemical detection of hepatitis C virus-infected hepatocytes in chronic liver disease with monoclonal antibodies to core, envelope and NS3 regions of the hepatitis C virus genome. Hepatology 16 (1992) 306-311
30. Holland J., Spindler K., Horodyski F., Grabau E., Nichol S., and VandePol S. Rapid evolution of RNA genomes. Science 215 (1982) 1577-1585
31. Houghton M., Weiner A., Han J., Kuo G., and Choo Q.L. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 14 (1991) 381-388
32. Hu K.Q., and Tong M.J. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29 (1999) 1311-1316
33. Huang X., Barchi Jr. J.J., Lung F.D., Roller P.P., Nara P.L., Muschik J., and Garrity R.R. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135. Biochemistry 36 (1997) 10846-10856
34. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., MacSween R.N., et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22 (1995) 696-699
35. Kato N., Sekiya H., Ootsuyama Y., Nakazawa T., Hijikata M., Ohkoshi S., and Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 67 (1993) 3923-3930
36. Khan M.H., Farrell G.C., Byth K., Lin R., Weltman M., George J., Samarasinghe D., Kench J., Kaba S., Crewe E., and Liddle C. Which patients with hepatitis C develop liver complications?. Hepatology 31 (2000) 513-520
37. Kim W.R. The burden of hepatitis C in the United States. Hepatology 36 (2002) S30-S34
38. Knodell R.G., Ishak K.G., Black W.C., Chen T.S., Craig R., Kaplowitz N., Kiernan T.W., and Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
39. Koizumi K., Enomoto N., Kurosaki M., Murakami T., Izumi N., Marumo F., and Sato C. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22 (1995) 30-35
40. Korber B. HIV signature and sequence variation analysis. In: Rodrigo A.G., and Learn G.H. (Eds). Computational Analysis of HIV Molecular Sequences (2000), Kluwer Academic Publishers, Dordrecht, Netherlands 55-72
41. Korber B., and Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res. Hum. Retrovir. 8 (1992) 1549-1560
42. Korber B.T., Kunstman K.J., Patterson B.K., Furtado M., McEvilly M.M., Levy R., and Wolinsky S.M. Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J. Virol. 68 (1994) 7467-7481
43. Kumar U., Monjardino J., and Thomas H.C. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 106 (1994) 1072-1075
44. Kurosaki M., Enomoto N., Marumo F., and Sato C. Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection. Hepatology 18 (1993) 1293-1299
45. Lemey P., Kosakovsky Pond S.L., Drummond A.J., Pybus O.G., Shapiro B., Barroso H., Taveira N., and Rambaut A. Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput. Biol. 3 (2007) e29
46. Li Y., Luo L., Rasool N., and Kang C.Y. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J. Virol. 67 (1993) 584-588
47. Lindenbatch B.D., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th ed. (2001), Lippincott Williams & Wikins, Philadelphia, PA 991-1041
48. Lu L., Nakano T., Orito E., Mizokami M., and Robertson B.H. Evaluation of accumulation of hepatitis C virus mutations in a chronically infected chimpanzee: comparison of the core, E1, HVR1, and NS5b regions. J. Virol. 75 (2001) 3004-3009
49. Lyra A.C., Fan X., Lang D.M., Yusim K., Ramrakhiani S., Brunt E.M., Korber B., Perelson A.S., and Di Bisceglie A.M. Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology 123 (2002) 1485-1493
50. Martell M., Esteban J.I., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., and Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66 (1992) 3225-3229
51. McAllister J., Casino C., Davidson F., Power J., Lawlor E., Yap P.L., Simmonds P., and Smith D.B. Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J. Virol. 72 (1998) 4893-4905
52. McMahon B.J., Hennessy T.W., Christensen C., Bruden D., Sullivan D.G., Homan C., Deubner H., Bruce M.G., Livingston S., Williams J., and Gretch D.R. Epidemiology and risk factors for hepatitis C in Alaska Natives. Hepatology 39 (2004) 325-332
53. Meunier J.C., Fournillier A., Choukhi A., Cahour A., Cocquerel L., Dubuisson J., and Wychowski C. Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J. Gen. Virol. 80 Pt 4 (1999) 887-896
54. Morishima C., Polyak S.J., Ray R., Doherty M.C., Di Bisceglie A.M., Malet P.F., Bonkovsky H.L., Sullivan D.G., Gretch D.R., Rothman A.L., Koziel M.J., and Lindsay K.L. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J. Infect. Dis. 193 (2006) 931-940
55. Nei M., and Gojobori T. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3 (1986) 418-426
56. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., and Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998) 103-107
57. Nowak M., and May R.M. Virus Dynamics (2000), Oxford University Press, New York
58. Op De Beeck A., Montserret R., Duvet S., Cocquerel L., Cacan R., Barberot B., Le Maire M., Penin F., and Dubuisson J. The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization. J. Biol. Chem. 275 (2000) 31428-31437
59. Pal S., Shuhart M.C., Thomassen L., Emerson S.S., Su T., Feuerborn N., Kae J., and Gretch D.R. Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo. J. Virol. 80 (2006) 2280-2290
60. Pawlotsky J.M., Pellerin M., Bouvier M., Roudot-Thoraval F., Germanidis G., Bastie A., Darthuy F., Remire J., Soussy C.J., and Dhumeaux D. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J. Med. Virol. 54 (1998) 256-264
61. Pazos F., and Valencia A. Similarity of phylogenetic trees as indicator of protein-protein interaction. Protein Eng. 14 (2001) 609-614
62. Pazos F., Ranea J.A., Juan D., and Sternberg M.J. Assessing protein co-evolution in the context of the tree of life assists in the prediction of the interactome. J. Mol. Biol. 352 (2005) 1002-1015
63. Pelletier S.J., Raymond D.P., Crabtree T.D., Iezzoni J.C., Sawyer R.G., Hahn Y.S., and Pruett T.L. Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation. Hepatology 32 (2000) 375-381
64. Penin F., Combet C., Germanidis G., Frainais P.O., Deleage G., and Pawlotsky J.M. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J. Virol. 75 (2001) 5703-5710
65. Polyak S.J., Faulkner G., Carithers Jr. R.L., Corey L., and Gretch D.R. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J. Infect. Dis. 175 (1997) 1101-1107
66. Polyak S.J., McArdle S., Liu S.L., Sullivan D.G., Chung M., Hofgartner W.T., Carithers Jr. R.L., McMahon B.J., Mullins J.I., Corey L., and Gretch D.R. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J. Virol. 72 (1998) 4288-4296
67. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
68. Qin H., Shire N.J., Keenan E.D., Rouster S.D., Eyster M.E., Goedert J.J., Koziel M.J., and Sherman K.E. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 105 (2005) 533-541
69. Ray S.C., Wang Y.M., Laeyendecker O., Ticehurst J.R., Villano S.A., and Thomas D.L. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J. Virol. 73 (1999) 2938-2946
70. Robertson B., Myers G., Howard C., Brettin T., Bukh J., Gaschen B., Gojobori T., Maertens G., Mizokami M., Nainan O., Netesov S., Nishioka K., Shin i T., Simmonds P., Smith D., Stuyver L., and Weiner A. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch. Virol. 143 (1998) 2493-2503
71. Rosa D., Campagnoli S., Moretto C., Guenzi E., Cousens L., Chin M., Dong C., Weiner A.J., Lau J.Y., Choo Q.L., Chien D., Pileri P., Houghton M., and Abrignani S. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1759-1763
72. Rosen H.R., Hinrichs D.J., Gretch D.R., Koziel M.J., Chou S., Houghton M., Rabkin J., Corless C.L., and Bouwer H.G. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 117 (1999) 926-932
73. Saitou N., and Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4 (1987) 406-425
74. Sanchez-Fueyo A., Gimenez-Barcons M., Puig-Basagoiti F., Rimola A., Sanchez-Tapias J.M., Saiz J.C., and Rodes J. Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J. Med. Virol. 65 (2001) 266-275
75. Scheuer P.J., Standish R.A., and Dhillon A.P. Scoring of chronic hepatitis. Clin. Liver Dis. 6 (2002) 335-347 v-vi
76. Seo T.K., Kishino H., and Thorne J.L. Estimating absolute rates of synonymous and nonsynonymous nucleotide substitution in order to characterize natural selection and date species divergences. Mol. Biol. Evol. 21 (2004) 1201-1213
77. Serfaty L., Aumaitre H., Chazouilleres O., Bonnand A.M., Rosmorduc O., Poupon R.E., and Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27 (1998) 1435-1440
78. Sheridan I., Pybus O.G., Holmes E.C., and Klenerman P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J. Virol. 78 (2004) 3447-3454
79. Shimizu Y.K., Hijikata M., Iwamoto A., Alter H.J., Purcell R.H., and Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68 (1994) 1494-1500
80. Shimizu Y.K., Igarashi H., Kiyohara T., Cabezon T., Farci P., Purcell R.H., and Yoshikura H. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223 (1996) 409-412
81. Simmonds P. Variability of hepatitis C virus. Hepatology 21 (1995) 570-583
82. Sobolev B.N., Poroikov V.V., Olenina L.V., Kolesanova E.F., and Archakov A.I. Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions. J. Viral Hepatitis 7 (2000) 368-374
83. Sullivan D.G., Wilson J.J., Carithers Jr. R.L., Perkins J.D., and Gretch D.R. Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J. Virol. 72 (1998) 10036-10043
84. Sullivan D.G., Bruden D., Deubner H., McArdle S., Chung M., Christensen C., Hennessy T., Homan C., Williams J., McMahon B.J., and Gretch D.R. Hepatitis C virus dynamics during natural infection are associated with long-term histological outcome of chronic hepatitis C disease. J. Infect. Dis. 196 (2007) 239-248
85. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 (1994) 4673-4680
86. van Doorn L.J., Capriles I., Maertens G., DeLeys R., Murray K., Kos T., Schellekens H., and Quint W. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J. Virol. 69 (1995) 773-778
87. Villano S.A., Vlahov D., Nelson K.E., Cohn S., and Thomas D.L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29 (1999) 908-914
88. Wack A., Soldaini E., Tseng C., Nuti S., Klimpel G., and Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur. J. Immunol. 31 (2001) 166-175
89. Wang X.H., Netski D.M., Astemborski J., Mehta S.H., Torbenson M.S., Thomas D.L., and Ray S.C. Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution. J. Virol. 81 (2007) 6513-6522
90. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
91. Weiner A.J., Brauer M.J., Rosenblatt J., Richman K.H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q.L., Houghton M., et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180 (1991) 842-848
92. Weiner A.J., Geysen H.M., Christopherson C., Hall J.E., Mason T.J., Saracco G., Bonino F., Crawford K., Marion C.D., Crawford K.A., et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3468-3472
93. WHO. Global surveillance and control of hepatitis C. J. Viral Hepatitis 6 (1999) 35-47
94. Wilson J.J., Polyak S.J., Day T.D., and Gretch D.R. Characterization of simple and complex hepatitis C virus quasispecies by heteroduplex gel shift analysis: correlation with nucleotide sequencing. J. Gen. Virol. 76 Pt 7 (1995) 1763-1771
95. Wu Z., Kayman S.C., Honnen W., Revesz K., Chen H., Vijh-Warrier S., Tilley S.A., McKeating J., Shotton C., and Pinter A. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J. Virol. 69 (1995) 2271-2278
96. Yagnik A.T., Lahm A., Meola A., Roccasecca R.M., Ercole B.B., Nicosia A., and Tramontano A. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40 (2000) 355-366
97. Zibert A., Schreier E., and Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208 (1995) 653-661
98. Zibert A., Meisel H., Kraas W., Schulz A., Jung G., and Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 25 (1997) 1245-1249